RPL19P16

Across TCGA pan-cancer cohorts, RPL19P16 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPL19P16’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RPL19P16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL19P16 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

COAD, LUAD, and KIRC are the cancer types where RPL19P16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL19P16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.474	<.001	10	view →
LUAD	All	III,IV	−0.724	<.001	9	view →
KIRC	Male	All	+0.210	<.001	7	view →
LUSC	Female	All	−0.755	<.001	6	view →
LIHC	All	All	+0.099	.002	3	view →
THCA	Female	II,III,IV	+0.262	.011	1	view →
HNSC	Female	All	−0.186	.041	1	view →
CHOL	All	All	+0.161	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RPL19P16–COAD

Open the COAD breakdown →